Mega Lifesciences (MEGA) Aktievy
Mega Lifesciences Public Company Limited, tillsammans med sina dotterbolag, tillverkar och säljer hälsokosttillskott, receptbelagda läkemedel, receptfria produkter, växtbaserade produkter, vitaminer och snabbrörliga konsumentvaror i Sydostasien och Afrika söder om Sahara. Mer information
| Snöflinga Score | |
|---|---|
| Värdering | 4/6 |
| Framtida tillväxt | 2/6 |
| Tidigare resultat | 5/6 |
| Finansiell hälsa | 5/6 |
| Utdelningar | 4/6 |
MEGA Community Fair Values
Create NarrativeSee what 15 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Mega Lifesciences Public Company Limited Konkurrenter
Prishistorik och prestanda
| Historiska aktiekurser | |
|---|---|
| Aktuell aktiekurs | ฿36.25 |
| 52 veckors högsta | ฿40.00 |
| 52 veckors lägsta | ฿27.75 |
| Beta | 0.30 |
| 1 månads förändring | -4.61% |
| 3 månaders förändring | 2.84% |
| 1 års förändring | 15.08% |
| 3 års förändring | -18.99% |
| 5 års förändring | -26.02% |
| Förändring sedan börsintroduktionen | 70.19% |
Senaste nyheter och uppdateringar
Uppdatering av berättelse • Jun 24
MEGA: Higher Margins And Lower Growth Will Likely Keep Shares Fairly Valued
Analysts have kept their fair value estimate for Mega Lifesciences steady at THB35.0, explaining that slightly softer revenue growth assumptions are offset by a higher profit margin outlook and a marginally lower future P/E multiple in their updated price target work. What’s in the News for Mega Lifesciences No recent company specific news items for Mega Lifesciences were identified in the provided sources.
Uppdatering av berättelse • Jun 07
MEGA: Stable Assumptions And Margin Outlook Will Drive Future Upside
Analysts have kept their price target for Mega Lifesciences unchanged at THB 41.14, citing only small adjustments to projected revenue growth, profit margins and future P/E assumptions that do not materially alter their overall view of the stock. What's in the News No recent company specific news for Mega Lifesciences has been provided in the available sources.Uppdatering av berättelse • May 24
MEGA: Higher Margin Outlook And Dividend Decision Will Support Future Upside
Analysts have trimmed their price target for Mega Lifesciences slightly to THB 41.14 from THB 41.17, reflecting updated assumptions that now pair a lower revenue growth outlook of 4.12% with a higher projected profit margin of 16.40% and a modestly lower future P/E of 16.67x. What's in the News A board meeting is scheduled for February 24, 2026, to consider a dividend payment proposal for the year ended December 31, 2025 (Key Developments).Uppdatering av berättelse • May 06
MEGA: Stable Outlook And Upcoming Dividend Decision Will Drive Further Upside
Analysts have kept their fair value estimate for Mega Lifesciences steady at THB41.17 per share, with only minimal model tweaks related to the discount rate, profit margin outlook and future P/E assumptions. What's in the News A board meeting is scheduled for February 24, 2026, to consider a dividend payment proposal for the year ended December 31, 2025 (Key Developments).Recent updates
Uppdatering av berättelse • Jun 24
MEGA: Higher Margins And Lower Growth Will Likely Keep Shares Fairly Valued
Analysts have kept their fair value estimate for Mega Lifesciences steady at THB35.0, explaining that slightly softer revenue growth assumptions are offset by a higher profit margin outlook and a marginally lower future P/E multiple in their updated price target work. What’s in the News for Mega Lifesciences No recent company specific news items for Mega Lifesciences were identified in the provided sources.Uppdatering av berättelse • Jun 07
MEGA: Stable Assumptions And Margin Outlook Will Drive Future Upside
Analysts have kept their price target for Mega Lifesciences unchanged at THB 41.14, citing only small adjustments to projected revenue growth, profit margins and future P/E assumptions that do not materially alter their overall view of the stock. What's in the News No recent company specific news for Mega Lifesciences has been provided in the available sources.Uppdatering av berättelse • May 24
MEGA: Higher Margin Outlook And Dividend Decision Will Support Future Upside
Analysts have trimmed their price target for Mega Lifesciences slightly to THB 41.14 from THB 41.17, reflecting updated assumptions that now pair a lower revenue growth outlook of 4.12% with a higher projected profit margin of 16.40% and a modestly lower future P/E of 16.67x. What's in the News A board meeting is scheduled for February 24, 2026, to consider a dividend payment proposal for the year ended December 31, 2025 (Key Developments).Uppdatering av berättelse • May 06
MEGA: Stable Outlook And Upcoming Dividend Decision Will Drive Further Upside
Analysts have kept their fair value estimate for Mega Lifesciences steady at THB41.17 per share, with only minimal model tweaks related to the discount rate, profit margin outlook and future P/E assumptions. What's in the News A board meeting is scheduled for February 24, 2026, to consider a dividend payment proposal for the year ended December 31, 2025 (Key Developments).Uppdatering av berättelse • Apr 21
MEGA: Higher Growth And Lower Margins Will Likely Keep Shares Fairly Valued
Analysts have lifted their price target on Mega Lifesciences from THB 32 to THB 35, citing updated assumptions around higher revenue growth, a slightly lower discount rate and a revised future P/E multiple, partially offset by a more conservative profit margin outlook. What's in the News Board meeting scheduled for Feb 24, 2026, to consider a dividend payment proposal for the year ended Dec 31, 2025 (company filing).Uppdatering av berättelse • Apr 06
MEGA: Stable Outlook And Upcoming Dividend Decision Will Support Upside
Analysts have maintained their price target for Mega Lifesciences at THB41.17, citing unchanged assumptions regarding fair value, discount rate, revenue growth, profit margin, and future P/E. What's in the News A board meeting is scheduled for February 24, 2026, to consider a dividend payment proposal for the year ended December 31, 2025 (Key Developments).Uppdatering av berättelse • Mar 23
MEGA: Higher Fair Value And Upcoming Dividend Decision Will Support Upside
Analysts have lifted their fair value estimate for Mega Lifesciences from THB 38.21 to THB 41.17, citing updated assumptions for long term profit margins and a higher future P/E multiple. What's in the News A board meeting is scheduled for February 24, 2026 for Mega Lifesciences Public Company Limited.
Uppdatering av berättelse • Mar 09
MEGA: Higher Future P/E Will Support Upgraded Fair Value Outlook
Analysts have lifted their price target for Mega Lifesciences from THB 41.60 to THB 45.00. They highlighted updated assumptions that include slightly lower revenue growth and profit margins, together with a higher future P/E multiple.Uppdatering av berättelse • Feb 23
MEGA: Updated Discount Rate And Margins Will Support Fair Pricing Ahead
Analysts have raised their price target on Mega Lifesciences to THB 38.21 from THB 34.58, citing updated assumptions related to slightly lower discount rates, adjusted revenue growth, modestly different profit margins and a revised future P/E multiple. Valuation Changes Fair Value: THB 34.58 to THB 38.21, indicating a modest uplift in the assessed share valuation.Uppdatering av berättelse • Feb 09
MEGA: Fair Outlook Will Balance Softer Margins With Stronger Revenue Expectations
Narrative update on Mega Lifesciences The analyst price target for Mega Lifesciences has been lifted from ฿39.00 to ฿41.60, with analysts linking this change to updated assumptions for slightly lower discount rates, higher forecast revenue growth, a modestly softer profit margin, and a higher future P/E multiple. Valuation Changes Fair Value Estimate: Raised from THB 39.00 to THB 41.60, a small uplift in the assessed equity value.Uppdatering av berättelse • Jan 25
MEGA: Stable Assumptions And Margins Will Support Fair Pricing Ahead
The analyst price target for Mega Lifesciences remains unchanged at ฿34.58, with analysts citing consistent assumptions for fair value, discount rate, revenue growth, profit margin, and future P/E. Valuation Changes Fair value: Unchanged at THB34.58 per share, with no adjustment to the underlying assumptions.Uppdatering av berättelse • Jan 10
MEGA: Higher Margin Assumptions Will Likely Leave Shares Overvalued
The analyst fair value estimate for Mega Lifesciences has been adjusted from ฿26.00 to ฿32.00, with analysts pointing to updated assumptions around revenue growth, profit margins and forward P/E to support the higher target. Valuation Changes The fair value estimate has risen from THB 26.00 to THB 32.00 per share, reflecting updated assumptions in the model.Uppdatering av berättelse • Dec 24
MEGA: Stable Margins And Earnings Outlook Will Support Fair Pricing Ahead
Analysts have reaffirmed their price target on Mega Lifesciences at THB 34.58 per share, citing unchanged assumptions for discount rate, revenue growth, profit margins, and future valuation multiples, which together support a steady outlook for the company’s fair value. Valuation Changes Fair Value: Unchanged at approximately THB 34.58 per share, indicating no revision to the overall equity valuation.Uppdatering av berättelse • Dec 09
MEGA: Stable Margins And Earnings Outlook Will Support Fair Pricing Ahead
Analysts have maintained their price target on Mega Lifesciences at THB 34.58 per share, reflecting steady assumptions on revenue growth, profit margins, and valuation multiples despite the latest review of fundamentals. Valuation Changes Fair Value: Unchanged at approximately THB 34.58 per share, indicating no revision to the core valuation thesis.Uppdatering av berättelse • Nov 25
MEGA: Improved Profit Margins And Revenue Estimates Suggest Fair Valuation Ahead
Analysts have raised their price target for Mega Lifesciences from THB 32.14 to THB 34.58. This reflects improved revenue growth forecasts and a slightly stronger profit margin outlook.Ny berättelse • Jun 01
Expansion In Indonesia And Vietnam Will Fuel Emerging Wellness Markets
Strategic expansion in high-growth markets and local manufacturing reduce operational risks and support sustainable revenue and margin growth.Aktieägarnas avkastning
| MEGA | TH Pharmaceuticals | TH Marknad | |
|---|---|---|---|
| 7D | 1.4% | -2.6% | -2.7% |
| 1Y | 15.1% | -9.5% | 20.3% |
Avkastning vs industri: MEGA översteg TH Pharmaceuticals branschen som gav -9.2 % under det senaste året.
Avkastning vs Marknaden: MEGA presterade sämre än TH marknaden som gav 22 % under det senaste året.
Prisvolatilitet
| MEGA volatility | |
|---|---|
| MEGA Average Weekly Movement | 3.7% |
| Pharmaceuticals Industry Average Movement | 6.1% |
| Market Average Movement | 4.0% |
| 10% most volatile stocks in TH Market | 9.5% |
| 10% least volatile stocks in TH Market | 2.0% |
Stabil aktiekurs: MEGA har inte haft någon betydande prisvolatilitet under de senaste 3 månaderna jämfört med marknaden för TH.
Volatilitet över tid: MEGA s veckovolatilitet ( 4% ) har varit stabil under det senaste året.
Om företaget
| Grundad | Anställda | VD OCH KONCERNCHEF | Webbplats |
|---|---|---|---|
| 1982 | n/a | Vivek Dhawan | www.megawecare.com |
Mega Lifesciences Public Company Limited, tillsammans med sina dotterbolag, tillverkar och säljer hälsokosttillskott, receptbelagda läkemedel, receptfria produkter, växtbaserade produkter, vitaminer och snabbrörliga konsumentvaror i Sydostasien och Afrika söder om Sahara. Bolaget är verksamt inom tre segment: Varumärken, distribution och tillverkning av originalutrustning (OEM). Företaget tillhandahåller olika läkemedel för allergier, blodcirkulation och minne, ben och leder, lever och matsmältning, diabetes, ögon, hjärta och hudvård, smärta, sömn, välbefinnande, växtbaserade läkemedel, hosta och förkylning, vitaminer, probiotika, medicinsk och sportnutrition samt vårdprodukter för barn, män och kvinnor.
Mega Lifesciences Public Company Limited Sammanfattning av grunderna
| MEGA grundläggande statistik | |
|---|---|
| Börsvärde | ฿31.61b |
| Vinst(TTM) | ฿2.19b |
| Intäkter(TTM) | ฿14.53b |
14.4x
P/E-förhållande2.2x
P/S-förhållandeÄr MEGA övervärderat?
Se Verkligt värde och värderingsanalysResultat & intäkter
| MEGA resultaträkning (TTM) | |
|---|---|
| Intäkter | ฿14.53b |
| Kostnad för intäkter | ฿6.89b |
| Bruttovinst | ฿7.64b |
| Övriga kostnader | ฿5.45b |
| Intäkter | ฿2.19b |
Senast redovisade vinst
Jun 30, 2026
Nästa vinstdatum
Nov 13, 2026
| Vinst per aktie (EPS) | 2.51 |
| Bruttomarginal | 52.57% |
| Nettovinstmarginal | 15.08% |
| Skuld/egenkapitalförhållande | 5.0% |
Hur har MEGA utvecklats på lång sikt?
Se historisk utveckling och jämförelseUtdelningar
4.7%
Aktuell utdelningsavkastning66%
UtbetalningskvotFöretagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/09/15 02:57 |
| Aktiekurs vid dagens slut | 2026/09/15 00:00 |
| Intäkter | 2026/06/30 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som används för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och handledningar på Youtube.
Lär dig mer om det som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Mega Lifesciences Public Company Limited bevakas av 15 analytiker. 7 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Thanapol Jiratanakij | CGS International |
| Chanpen Sirithanarattanakul | DBS Bank Ltd |
| Nantika Wiangphoem | DBS Bank Ltd |